Luke William Schroeder, MD - MUSC Shawn Jenkins Children's Hospital

Dr. Jacqueline Kraveka is an associate professor of pediatrics and a pediatric hematologist-oncologist at the Medical University of South Carolina (MUSC) in Charleston, South Carolina. She was born in Velasco, Cuba and immigrated to the United States when she was four years of age. Dr. Kraveka received her undergraduate degree from Columbia University in 1989 and her medical degree from Nova Southeastern University College of Osteopathic Medicine in 1994. She completed her residency in pediatrics at Miami Children's Hospital in 1997 and fellowship in pediatric hematology oncology at the Medical University of South Carolina in 2000.Since 2000, she has been on staff at the Medical University of South Carolina Children's Hospital.Dr. Kraveka's clinical practice is focused on pediatric oncology. Her clinical interests include neuroblastoma, pediatric sarcomas, pediatric precision medicine, and clinical trial development. She is actively involved in clinical pediatric research in the Children's Oncology Group (COG) and Beat Childhood Cancer (BCC) consortia and serves as the institutional principal investigator for these consortia. As such,Dr. Kraveka is responsible for the conduct of over 50 Phase I, II, and III clinical trials for pediatric oncology patients at MUSC. She has been involved in the development of over 10 pediatric clinical trials for children with cancer.Dr. Kraveka serves on the COG Neuroblastoma and Diversity and Health Disparities Committees and is a member of the BCC Executive and Scientific Committees. She has been honored as a &"Top Doctor&" and "Exceptional Women in Medicine&" by Castle Connolly. She was selected as a &"Health Care Hero&" by the Charleston Regional Business Journal. Dr. Kraveka is also very involved in translational and bench research and has the only research laboratory in South Carolina dedicated to pediatric cancer.Dr. Kraveka's current research focuses on sphingolipid and retinoid mediated therapies in pediatric cancers and the function and regulation of the enzyme dihydroceramide desaturase (DEGS-1) in pediatric cancer. The long-term goals of her research are to develop more effective treatments for children with cancer.

MUSC Health is a comprehensive healthcare system dedicated to providing high-quality medical care across various locations in South Carolina, including Charleston, Florence, and Orangeburg. With a strong emphasis on patient-centered care, the organization offers a wide range of services, including primary care, specialized treatments, and rehabilitation services. In addition to their clinical services, MUSC Health is committed to community involvement through initiatives like the Arts in Healing program and volunteer opportunities. Their focus on education and research further enhances their ability to deliver evidence-based practices, ensuring the best care for patients and families. Generated from the website

Andrew M. Atz, M.D. is a professor and chair of pediatrics at the Medical University of South Carolina (MUSC). He has amassed an important and productive career in cardiology-based patient oriented research. Instrumental in reporting the initial early human use of inhaled nitric oxide in patients with reversible pulmonary hypertension, he has subsequently expanded his research experience into multicenter clinical drug and management studies. He was the director of the pediatric cardiac intensive care unit (PCICU) at MUSC for 15 years until assuming the role of chief of pediatric cardiology in 2013. He is also director of the pediatric clinical trials group. He became chair of the Department of Pediatrics in 2017. Dr. Atz has been a principal investigator for NHLBI-sponsored Pediatric Heart Network (PHN) and is the network chair for three of the ongoing studies. He is also a principal investigator in the NICHD-sponsored Idea States Pediatric Clinical Trials Network. Dr. Atz has acknowledged expertise in pediatric cardiac intensive care, with a special interest in the clinical management of perioperative care and pulmonary hypertension. He has received funding for more than 40 multi-institutional prospective clinical trials assessing pharmacologic therapies and monitoring devices.